THNSL2

Across TCGA pan-cancer cohorts, THNSL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated THNSL2 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher THNSL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated THNSL2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and OV show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where THNSL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.547	0.919	<.001	65	view →
LUAD	DFS	Median	All	0.865	0.527	.004	14	view →
LSCC	DFS	Median	All	0.883	1.000	.016	5	view →
OV	DFS	Quartile	All	1.000	0.612	.026	4	view →
HNSC	DFS	Median	III,IV	0.746	0.334	.014	2	view →
GBM	OS	Median	All	0.290	0.418	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

THNSL2–PDAC (OS)

Open the PDAC breakdown →